Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Sex Steroids Influence Brain-Derived Neurotropic Factor Secretion From Human Airway Smooth Muscle Cells
Wang, Sheng-Yu, Freeman, Michelle, Sathish, Venkatachalem , Prakash, Y. S. , Freeman, Michelle R, Wang, Sheng-Yu, Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Sathish, Venkatachalem

Journal of Cellular Physiology | November 13, 2015 | Volume: 231 | Issue: 7 | Pages: 1586-1592

10.1002/jcp.25254 | PMID 26566264 Get It

Impact of access to NCI‐ and NCCN‐designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis
Advani, Pooja , Yang, Dongyun , Ghosh, Radhika , Swaika, Abhisek, Foran, James M. , Colón‐Otero, Gerardo , Chanan‐Khan, Asher , Chanan-Khan, Asher, Ailawadhi, Sikander , Roy, Vivek

Cancer | November 13, 2015 | Volume: 122 | Issue: 4 | Pages: 618-625

10.1002/cncr.29771 | PMID 26565660 Get It

BACKGROUNDNational Cancer Institute (NCI)/National Comprehensive Cancer Network (NCCN)–designated cancer centers (CCs) offer patients state‐of‐the‐art treatment, but their impact on multiple myeloma (MM) patient outcomes has not been evaluated.METHODSAdult MM patients diagnosed between 1973 and 2011 were identified from the Surveillance, Epidemiology, and End Results database and were stratified by the county of residence at the time of diagnosis and the year of CC designation. The influence of NCI/NCCN CC access, race, and the year of diagnosis on overall survival (OS) was evaluated with a Cox regression model.RESULTSA statistically significant OS improvement was noted in patients diagnosed after 1995 with access to 2 or more NCI CCs overall (P = .002 for 1996‐2002; P < .001 for 2003‐2011) and by race for whites (hazard ratio [HR] for 1996‐2002, 0.85; 95% confidence interval [CI], 0.78‐0.91; HR for 2003‐2011, 0.85; 95% CI, 0.79‐0.91) but not for nonwhites. For NCCN access, improvement was seen in 1996‐2002 (P = .003), in 2003‐2011 (P < .001), and by race for whites (HR, 0.917; 95% CI, 0.88‐0.95) and nonwhites (0.94; 95% CI, 0.89‐0.99), but within nonwhites, this was true only for African Americans (AAs; HR, 0.88; 95% CI, 0.81‐0.97) and not for Asians, Hispanics, or Native Americans.CONCLUSIONSImprovement in OS was seen in MM patients diagnosed after 1995 with access to 1 NCCN CC or 2 or more NCI CCs. NCI access benefited only whites, whereas NCCN access benefited only white and AA patients. No OS benefit was seen for any subgroup with access to only 1 NCI center. Eliminating racial disparities in health care access and utilization is needed to improve outcomes. Cancer 2016;122:618–625. © 2015 American Cancer Society.
It's not too late: a proposal to standardize the terminology of “late‐onset” cytomegalovirus infection and disease in solid organ transplant recipients
Razonable, Raymund R. , Blumberg, Emily A.

Transplant Infectious Disease | November 13, 2015 | Volume: 17 | Issue: 6 | Pages: 779-784

10.1111/tid.12447 | PMID 26771688 Get It

Salvage autologous fascial sling after failed synthetic midurethral sling: Greater than 3‐year outcomes
Petrou, Steven P. , Davidiuk, Andrew, Rawal, Bhupendra, Thiel, David D. , Davidiuk, Andrew J, Arnold, Michelle, Arnold, Michelle L.

International Journal of Urology | November 13, 2015 | Volume: 23 | Issue: 2 | Pages: 178-181

10.1111/iju.13003 | PMID 26563492 Get It

ObjectiveTo determine long‐term surgical outcomes of salvage autologous fascial sling placement after a failed synthetic midurethral sling.MethodsWomen who had undergone autologous fascial sling placement without concomitant pelvic surgery for a failed synthetic midurethral sling utilizing mesh with a minimum follow up of 36 months were identified. Charts were reviewed, and patients were contacted by telephone. Success was determined by the Patient Global Impression of Improvement. Secondary measures included the Incontinence Severity Index questionnaire, patient recommendation of the autologous fascial sling and need for further incontinence surgery.ResultsA total of 35 patients met the criteria, and 21 were successfully contacted. Of those contacted, the median age at surgery was 67 years (range 53–81 years) and at the time of the survey was 75 years (range 63–84 years) with median follow up of 74 months (range 36–127 years). Preoperatively, 12 patients (57.1%) had urethral hypermobility and 13 patients (61.9%) had mixed urinary incontinence. Eight patients (38.1%) had concomitant sling excision with five of those combined with urethrolysis at the time of the salvage operation. Patient Global Impression of Improvement success was noted in 16 patients (76.2%). A total of 11 patients (52.4%) were dry or had slight incontinence by the Incontinence Severity Index. One patient required additional anti‐incontinence surgery (4.8%). A total of 18 patients (85.7%) recommended the autologous fascial sling. No statistical impact was noted with sling excision (P = 0.62), mixed urinary incontinence (P = 0.61), age at surgery (P = 0.23), age at follow up (P = 0.15), length of follow up (P = 0.71) or first surgery type (transobturator tape vs retropubic; P = 1.00).ConclusionsAutologous fascial sling provides reasonable long‐term success as a salvage operation for failed midurethral slings.
Vasculitic neuropathy following exposure to minocycline
Baratta, John M. , Dyck, P. James B. , Brand, Patricio , Thaisetthawatkul, Pariwat , Engelstad, JaNean , Goodman, Brent P., Goodman, Brent, Karam, Chafic , Baratta, John M

Neurology Neuroimmunology & Neuroinflammation | November 13, 2015 | Volume: 3 | Issue: 1 | Pages: No page available

10.1212/nxi.0000000000000180 | PMID 26601119 Get It

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women
Leal, Alexis D. , Thompson, Carrie A. , Wang, Alice H., Vierkant, Robert A. , Ross, Julie A. , Virnig, Beth A , Habermann, Thomas M. , Mesa, Ruben A. , Cerhan, James R. , Vierkant, Robert A

Cancer Epidemiology, Biomarkers & Prevention | November 13, 2015 | Volume: 25 | Issue: 1 | Pages: 151-157

10.1158/1055-9965.epi-15-0613 | PMID 26564251 Get It

AbstractBackground: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown.Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression.Results: After &gt;250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19–2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34–0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11–2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12–0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for &gt;36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations.Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN.Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes. Cancer Epidemiol Biomarkers Prev; 25(1); 151–7. ©2015 AACR.
Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis
Tomassetti, Sara , Wells, Athol U. , Costabel, Ulrich , Cavazza, Alberto , Colby, Thomas V. , Rossi, Giulio , Sverzellati, Nicola , Carloni, Angelo, Carretta, Elisa , Buccioli, Matteo , Tantalocco, Paola, Ravaglia, Claudia , Gurioli, Christian, Dubini, Alessandra, Piciucchi, Sara , Ryu, Jay H. , Poletti, Venerino , Rossi, Antônio , Ryu, Jay H , Ravaglia, Claudia

American Journal of Respiratory and Critical Care Medicine | November 12, 2015 | Volume: 193 | Issue: 7 | Pages: 745-752

10.1164/rccm.201504-0711oc | PMID 26562389 Get It

Abstract Rationale Surgical lung biopsy is often required for a confident multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF). Alternative, less-invasive biopsy methods, such as bronchoscopic lung cryobiopsy (BLC), are highly desirable. Objectives To address the impact of BLC on diagnostic confidence in the multidisciplinary diagnosis of IPF. Methods In this cross-sectional study we selected 117 patients with fibrotic interstitial lung disease without a typical usual interstitial pneumonia pattern on high-resolution computed tomography. All cases underwent lung biopsies: 58 were BLC, and 59 were surgical lung biopsy (SLB). Two clinicians, two radiologists, and two pathologists sequentially reviewed clinical-radiologic findings and biopsy results, recording at each step in the process their diagnostic impressions and confidence levels. Measurements and Main Results We observed a major increase in diagnostic confidence after the addition of BLC, similar to SLB (from 29 to 63%, P = 0.0003 and from 30 to 65%, P = 0.0016 of high confidence IPF diagnosis, in the BLC group and SLB group, respectively). The overall interobserver agreement in IPF diagnosis was similar for both approaches (BLC overall kappa, 0.96; SLB overall kappa, 0.93). IPF was the most frequent diagnosis (50 and 39% in the BLC and SLB group, respectively; P = 0.23). After the addition of histopathologic information, 17% of cases in the BLC group and 19% of cases in the SLB group, mostly idiopathic nonspecific interstitial pneumonia and hypersensitivity pneumonitis, were reclassified as IPF. Conclusions BLC is a new biopsy method that has a meaningful impact on diagnostic confidence in the multidisciplinary diagnosis of interstitial lung disease and may prove useful in the diagnosis of IPF. This study provides a robust rationale for future studies investigating the diagnostic accuracy of BLC compared with SLB.
Diagnostic accuracy of thyroid nodule growth to predict malignancy in thyroid nodules with benign cytology: systematic review and meta‐analysis
Ospina, Naykky Singh , Maraka, Spyridoula , DeYcaza, Ana Espinosa, O’Keeffe, Derek T. , Brito, Juan P. , Gionfriddo, Michael R. , Castro, M. Regina , Erwin, Patricia J., Montori, Víctor M. , Singh Ospina, Naykky, Espinosa DeYcaza, Ana, O'Keeffe, Derek, Erwin, Patricia, Morris, John C., Maraka, Spyridoula , Montori, Victor M , Singh Ospina, Naykky , Brito, Juan P

Clinical Endocrinology | November 12, 2015 | Volume: 85 | Issue: 1 | Pages: 122-131

10.1111/cen.12975 | PMID 26562828 Get It

SummaryBackgroundThyroid ultrasound to assess for nodular growth is commonly performed during the follow‐up of patients with benign thyroid nodules, with the goal of identifying patients with a missed diagnosis of thyroid cancer. The objective of this study was to summarize the evidence regarding the diagnostic accuracy of growth during follow‐up of benign thyroid nodules for thyroid cancer.MethodsWe searched multiple electronic databases using a search strategy designed by an experienced medical librarian from inception to March 2015. Eligible studies included patients with benign thyroid nodules assessed for growth during follow‐up and evaluated for thyroid cancer either by surgical histology or a repeat fine needle aspiration biopsy. Reviewers working independently and in duplicate recorded data and assessed each study.ResultsThe seven eligible studies lacked safeguards against bias and generated results that were imprecise with wide confidence intervals and inconsistent across studies. This warrants very low confidence in these results. The odds of nodule growth in patients with thyroid cancer on histopathology over these odds in patients without thyroid cancer (diagnostic odds ratio) was 0·58 (95% CI: 0·26–1·3); the diagnostic odds ratio was 2·2 (95% CI: 0·26–18) when an abnormal repeat biopsy was the reference standard.ConclusionThe body of evidence linking nodule growth with thyroid cancer during the follow‐up of benign nodules warrants very low confidence. In the era of high‐value health care, the commonplace practice of following benign thyroid nodules with serial ultrasound assessment of growth to diagnose cancer can be questioned, calling for imminent evaluation.
When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?
Ospina, Naykky Singh , Maraka, Spyridoula , Montori, Víctor M. , Thompson, Geoffrey B. , Young, William F., Singh Ospina, Naykky, Maraka, Spyridoula , Montori, Victor M , Singh Ospina, Naykky

Clinical Endocrinology | November 12, 2015 | Volume: 84 | Issue: 1 | Pages: 13-16

10.1111/cen.12972 | PMID 26562483 Get It

SummaryPatients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1–2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate–high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co‐ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.
What Next for Newly Diagnosed Glioblastoma?
Domingo‐Musibay, Evidio , Galanis, Evanthia

Future Oncology | November 12, 2015 | Volume: 11 | Issue: 24 | Pages: 3273-3283

10.2217/fon.15.258 | PMID 26558493 Get It